Cartesian Therapeutics Inc
F:1S70
Cartesian Therapeutics Inc
F:1S70
Price:
8.3
EUR
-6.74%
Market Cap:
€215.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cartesian Therapeutics Inc
F:1S70
|
US |
|
A
|
Aristocrat Leisure Ltd
F:AC8
|
AU |
|
E
|
Electronic Arts Inc
DUS:ERT
|
US |
|
N
|
New China Life Insurance Co Ltd
XBER:NCL
|
CN |
|
CAE Inc
TSX:CAE
|
CA |
|
General Dynamics Corp
NYSE:GD
|
US |
|
C
|
Chocoladefabriken Lindt & Spruengli AG
DUS:LSPP
|
CH |
|
V
|
Valtecne SpA
MIL:VLT
|
IT |
|
R
|
Resona Holdings Inc
SWB:DW1
|
JP |
Wall St Price Targets
1S70 Price Targets Summary
Cartesian Therapeutics Inc
Cartesian Therapeutics Inc
Wall Street analysts forecast 1S70 stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for 1S70 is 26.49 EUR with a low forecast of 12.41 EUR and a high forecast of 35.46 EUR.
Lowest Forecast
Price Target
12.41
EUR
49% Upside
Average Forecast
Price Target
26.49
EUR
219% Upside
Highest Forecast
Price Target
35.46
EUR
327% Upside
Cartesian Therapeutics Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 1S70's stock price target?
Price Target
26.49
EUR
26.49
EUR
According to Wall Street analysts, the average 1-year price target for 1S70 is 26.49 EUR with a low forecast of 12.41 EUR and a high forecast of 35.46 EUR.
What is the Revenue forecast for Cartesian Therapeutics Inc?
Projected CAGR
105%
105%
Over the last 10 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 8 years is 105%.
